Contrast-induced nephropathy: searching for new solutions to prevent its development

D.D. Ivanov


Contrast-induced nephropathy (CIN) is the main cause of acute kidney injury and worsens the prognosis of chronic kidney disease. To evaluate the clinical risk score of CIN development, various medical calculators are proposed. The main criterion for assessing the possible development of CIN is the initial glomerular filtration rate presented by estimated glomerular filtration rate. Toxic effect of contrast substances is realized through the properties of the molecule of contrast itself (tubular cell damage) and induced ischemia with oxidative stress and vasoconstriction. Existing methods for preventing the development of CIN are based on reducing the toxic effect of a contrast agent and preventing hypoxic kidney shock. The drugs currently proposed are acetylcysteine, statins, and some other approaches as well as hemodialysis. However, the evidence base is the most informative for hydration, which should be used before the introduction of a contrast agent, along with the minimization of the dose of contrast. Nevertheless, no final solution has been found to prevent the development of CIN. We have proposed the use of edaravone, which has an evidence base for ischemic stroke, to prevent the development of CIN. Three patients with chronic kidney disease stage 3b were given 30 mg edaravone twice a day before contrast media infusion and during two days after contrast administration. In two patients, CIN was avoided. The proposed approach requires future research to evaluate its effectiveness.


contrast-induced nephropathy; hydration; chronic kidney disease; edaravone

Full Text:



National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266.

Jeon J, Kim S, Yoo H, et al. Risk Prediction for Contrast-Induced Nephropathy in Cancer Patients Undergoing Computed Tomography under Preventive Measures. J Oncol. 2019 Apr 1;2019:8736163. doi: 10.1155/2019/8736163.

Kellum JA, Lameire, Aspelin P, et al. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kindey Int. 2012;2(1):1-138. doi:10.1038/kisup.2012.1.

Gurm HS, Seth M, Kooiman J, Share D. A novel tool for reliable and accurate prediction of renal complications in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2013 Jun 4;61(22):2242-8. doi: 10.1016/j.jacc.2013.03.026.

Van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients : Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018 Jul;28(7):2856-2869. doi: 10.1007/s00330-017-5247-4.

Shamekhi Amiri F. Recent advances in the treatment of renal diseases with nebivolol: A literature review. Nephrol Ther. 2016 Jun;12(3):140-8. doi: 10.1016/j.nephro.2016.01.011.

Ivanov DD, Rostaing L. Diuretics and advanced features of nephroprotection. Počki. 2019;8(1):2-6. doi: 10.22141/2307-1257.8.1.2019.157790. (in Russian).

Maioli M, Toso A, Leoncini M, et al. Bioimpedance-Guided Hydration for the Prevention of Contrast-Induced Kidney Injury: The HYDRA Study. J Am Coll Cardiol. 2018 Jun 26;71(25):2880-2889. doi: 10.1016/j.jacc.2018.04.022.

Yang J, Peng Y, Tsai S, et al. The molecular mechanism of contrast-induced nephropathy (CIN) and its link to in vitro studies on iodinated contrast media (CM). Biomedicine (Taipei). 2018 Mar;8(1):1. doi: 10.1051/bmdcn/2018080101.

Hossain MA, Costanzo E, Cosentino J, et al. Contrast-induced nephropathy: Pathophysiology, risk factors, and prevention. Saudi J Kidney Dis Transpl. 2018 Jan-Feb;29(1):1-9. doi: 10.4103/1319-2442.225199.

Enomoto M, Endo A, Yatsushige H, Fushimi K, Otomo Y. Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy. Stroke. 2019 Mar;50(3):652-658. doi: 10.1161/STROKEAHA.118.023815.

Watanabe K, Tanaka M, Yuki S, Hirai M, Yamamoto Y. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J Clin Biochem Nutr. 2018 Jan;62(1):20-38. doi: 10.3164/jcbn.17-62.

Copyright (c) 2019 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© "Publishing House "Zaslavsky", 1997-2019


   Seo анализ сайта